ReviewDiscover oncology2025
Emerging trends and global collaboration in Paclitaxel resistance research for breast cancer: a comprehensive bibliometric study.
Review in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Integrated Computational Modeling Reveals a Structurally Plausible Transient Paclitaxel-NK2R Interaction.Bioengineering (Basel, Switzerland) · 2026Article
- DNMT3B- SLC25A6 axis-mediated DNA methylation regulates ferroptosis to promote paclitaxel resistance in triple-negative breast cancer.Frontiers in cell and developmental biology · 2026Article
- Honokiol Suppresses Stemness and Sensitizes Triple-Negative Breast Cancer to Chemotherapy via YAP/TAZ-TEAD Inhibition.Oncology research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Paclitaxel, a compound that targets microtubules in cancer cells and inhibits mitosis, has been used as a first-line treatment for recurrent or metastatic breast cancer for over three decades. Research into paclitaxel resistance has yielded thousands of articles. However, this body of research has not been analyzed systematically and quantitatively. This study employs bibliometric analysis and visualisation techniques using VOSviewer and CiteSpace software to elucidate the contributions from countries and institutions, collaboration patterns, journal publication trends, research evolution, and current hotspots. Our findings reveal that leading research institutions in the United States, Europe, and East Asia hold significant advantages in this field. Specifically, the United States contributed the most to this field, with MD Anderson Cancer Center being the most prominent research institution and having a broad collaboration network. Prestigious oncology journals serve as primary platforms for disseminating key findings, with Cancer Research publishing the most relevant articles and having the highest co-citation frequency. We identified the main research branches by analysing keyword co-occurrence and keyword bursts, including treatment methods, drug delivery, mechanisms, and cellular response. Current research focuses on unveiling resistance mechanisms and exploring new therapeutic strategies. Paclitaxel resistance in breast cancer, particularly in TNBC and metastatic cases, remains an active and critical research area. Integrating nanotechnology into drug development and therapeutic strategies is a current focal point and promises to be a significant future direction. These insights highlight a strategic direction for future research, including strengthening international partnerships, deepening understanding of resistance mechanisms, and applying engineered therapeutics for targeted breast cancer treatments.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.